Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06139744
Other study ID # KY20230915-01
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date November 2023
Est. completion date November 2024

Study information

Verified date November 2023
Source Nanjing First Hospital, Nanjing Medical University
Contact Zhenyu Zhang
Phone 02552271029
Email ahzhangzhenyu@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project is a single center, randomized, controlled clinical trial evaluating the effects of DAO enzyme dietary supplement on symptoms of irritable bowel syndrome. These participants are randomized to either a 4-week group with DAO enzyme dietary supplement or placebo. The participants are required to fill out IBS-SSS and IBS-QOL questionnaires and record their IBS symptom improvement, IBS treatment drug use, compliance and adverse reactions every evening. At the same time, the patients' diet is continuously recorded for 3 days by 24-hour diet review method in Visit 0, Visit 1 and Visit 2, respectively, to inform the patients to avoid large fluctuations in diet structure. On days 0, 14 and 28, the subjects are asked to visit the hospital offline. The staff check with the subjects in detail according to the scale and questionnaire contents, and review the general situation and questionnaire in the previous 2 weeks. On the 7th and 21st day, the staff contact the subjects online to provide guidance and remind the subjects to fill in the scale and questionnaire. In addition, oral mucosal samples, urine and feces will be collected for identifying mutations in the genetic DAO enzyme coding gene, histamine detection and 16sRNA sequencing, respectively.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date November 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age 18-65 years old; 2. Diagnosed with IBS according to Rome IV diagnostic criteria; Recurrent abdominal pain occurred on an average of at least 1 day per week in the past 3 months and was associated with two or more of the following criteria: i. Related to defecation; ii. Associated with changes in bowel frequency; iii. Correlated with fecal morphological changes. The symptoms appeared at least 6 months before diagnosis, and the above diagnostic criteria were met in the last 3 months. 3. Voluntarily participate in the experiment and sign the informed consent. Exclusion Criteria: 1. Patients with endoscopy examinations which suggest chronic intestinal diseases other than IBS, such as inflammatory bowel disease, celiac disease, gastric and duodenal ulcers, parasitic or bacterial intestinal infections; 2. Pregnant and lactating women; 3. Patients suffering from serious concomitant diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease, tumor; 4. Alcoholism.

Study Design


Intervention

Drug:
DAO supplement
One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.
Placebo
Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.

Locations

Country Name City State
China Zhenyu Zhang Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing First Hospital, Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Effect of diet difference on treatment of IBS with dehydrated pea seedling powder The effects of dietary differences on the treatment of IBS with dehydrated pea seedling powder were evaluated by 24-hour diet review. 4 weeks of study medication administration
Other Histamine concentration in urine The effect of dehydrated pea seedling powder on histamine concentration was evaluated by detecting histamine concentration in urine. 4 weeks of study medication administration
Other Fecal intestinal flora Changes of fecal intestinal flora in patients before and after oral administration of dehydrated pea seedling powder 4 weeks of study medication administration
Other The expression of diamine oxidase in IBS patients The expression of diamine oxidase in IBS patients before study medication administration
Other Drug use in subjects The effects of dehydrated pea seedling powder interventions on drug use in subjects 4 weeks of study medication administration
Other Adverse events The occurrence of adverse events 4 weeks of study medication administration
Primary IBS-SSS The effects of DAO enzyme dietary supplement from dehydrated pea seedling powder on IBS symptoms were evaluated by the Severity Scale of irritable bowel Syndrome (IBS-SSS) and the changes of several independent symptoms. 4 weeks of study medication administration
Secondary IBS-QOL The overall improvement of quality of life in IBS patients with DAO enzyme dietary supplement from dehydrated pea seedling powder was evaluated by the irritable bowel Syndrome Quality of Life Questionnaire (IBS-QOL). 4 weeks of study medication administration
Secondary Improvement of symptoms listed in the Rome IV diagnostic criteria for IBS Number of days with abdominal pain in the past week;
Number of days of defecation-related abdominal pain in the past week;
Frequency of bowel movements;
Changes in stool pattern according to the Bristol stool Classification Scale.
4 weeks of study medication administration
See also
  Status Clinical Trial Phase
Withdrawn NCT02841878 - Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome N/A
Completed NCT02875847 - Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients Phase 2
Completed NCT02842281 - Microbiome Fructan Metabolism and Symptoms in Childhood IBS N/A
Completed NCT02092402 - Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome N/A
Completed NCT03964103 - qQ-lab Daily-IBS for Irritable Bowel Syndrome N/A
Completed NCT00401479 - A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers Phase 1
Completed NCT00421707 - Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome Phase 2
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT01908465 - Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial Phase 4
Completed NCT01787253 - Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
Completed NCT00376896 - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers Phase 1
Completed NCT00904696 - Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome N/A
Recruiting NCT05453084 - Exercise and Irritable Bowel Syndrome (IBS) N/A
Completed NCT03550742 - Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients N/A
Terminated NCT01887002 - Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT01774695 - Physical Activity in IBS - a Long Term Follow up N/A
Completed NCT01204515 - Abdominal Symptom Phenotype Study in Children N/A
Completed NCT00067457 - Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Phase 3
Completed NCT00067561 - Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Phase 3
Not yet recruiting NCT05630703 - Mindfulness Training Versus Low (FODMAP) Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols Diet N/A